Rituximab therapy for chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) can vary in severity, with some patients requiring chemotherapy while others may not require treatment at all. Rituximab has been evaluated as a first‐line treatment option for CLL in combination with fludarabine and cyclophos‐phamide in patients requiring chemotherapy, and a licence application has been made. In this article, we consider the evidence for rituximab, and its potential place in therapy. Copyright © 2008 John Wiley & Sons, Ltd.